Applera Corporation today announced that its board of directors has formally approved the proposed separation of the Celera Group (NYSE:CRA) from Applera's remaining businesses.

Today in Anchorage, Alaska, international researchers will convene to discuss the use of the latest advances in genetic analysis technology to address the conservation and management of wild salmon in the Pacific Ocean.

Celera Genomics (NYSE:CRA), an Applera Corporation business, today announced that the National Institutes of Health (NIH) has awarded Celera approximately $900,000 to develop and commercialize an in vitro diagnostic (IVD) test for the highly pathogenic influenza A/H5 virus (Asian lineage, H5N1).

Strategy to Reduce Cash Burn Substantially and Accelerate Move to Profitability; Conference Call at 10 a.m.

Celera Diagnostics, a joint venture between the Applied Biosystems Group (NYSE:ABI) and Celera Genomics Group (NYSE:CRA) of Applera Corporation, today announced the publication of data showing that a novel locus on Chromosome 10 correlates strongly with increased risk for late-onset Alzheimer's disease.